Prognostic value of serological and PET/CT response kinetics in patients with multiple myeloma treated with BCMA CAR-T

Le résumé fourni par la source

Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) is now a standard of care for relapsed and refractory multiple myeloma (MM) with two approved drug products (i.e., idecabtagene vicleucel [ide-cel], ciltacabtagene autoleucel [cilta-cel]) [ 1 , 2 , 3 , 4 , 5 ]. Treatment with BCMA CAR-T in MM patients is characterized by rapid response kinetics, with a median time to first response and complete response (CR) of 1 and 3 months, respectively [ 1 , 2 , 3 , 4 , 5 ]. Patients who achieve a CR as the best overall response to BCMA CAR-T have significantly longer PFS [ 1 , 2 , 3 , 4 , 5 ], but these analyses are limited by immortal time bias and the prognostic significance of early categorical response attainment at specific landmark time points is unclear.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.